Thrivent Financial for Lutherans purchased a new position in Tilray Inc (NASDAQ:TLRY) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 50,028 shares of the company’s stock, valued at approximately $344,000.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. ETF Managers Group LLC increased its position in Tilray by 8.5% during the first quarter. ETF Managers Group LLC now owns 3,073,889 shares of the company’s stock valued at $21,148,000 after acquiring an additional 240,559 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Tilray by 52.8% during the 1st quarter. Commonwealth Equity Services LLC now owns 43,422 shares of the company’s stock valued at $298,000 after purchasing an additional 15,007 shares during the period. Swiss National Bank grew its stake in shares of Tilray by 4.9% during the 1st quarter. Swiss National Bank now owns 48,800 shares of the company’s stock valued at $336,000 after purchasing an additional 2,300 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Tilray during the 1st quarter valued at about $126,000. Finally, UBS Group AG lifted its stake in shares of Tilray by 252.3% in the 1st quarter. UBS Group AG now owns 12,293 shares of the company’s stock worth $85,000 after purchasing an additional 20,362 shares during the period. 7.94% of the stock is owned by institutional investors.
In other Tilray news, Director Michael Auerbach sold 220,711 shares of Tilray stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $7.38, for a total value of $1,628,847.18. Following the sale, the director now owns 588,306 shares of the company’s stock, valued at approximately $4,341,698.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Brendan Kennedy sold 350,000 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $8.20, for a total value of $2,870,000.00. Following the sale, the chief executive officer now directly owns 4,515,127 shares in the company, valued at $37,024,041.40. The disclosure for this sale can be found here. Insiders have sold a total of 687,377 shares of company stock valued at $5,471,842 in the last three months. Insiders own 16.75% of the company’s stock.
Shares of TLRY opened at $7.11 on Wednesday. The firm has a market cap of $887.76 million, a P/E ratio of -1.55 and a beta of 3.32. The company has a debt-to-equity ratio of 2.63, a current ratio of 1.98 and a quick ratio of 1.42. Tilray Inc has a 1 year low of $2.43 and a 1 year high of $49.49. The company has a 50 day simple moving average of $8.91 and a two-hundred day simple moving average of $11.83.
Tilray (NASDAQ:TLRY) last issued its earnings results on Monday, May 11th. The company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($1.29). The company had revenue of $52.20 million for the quarter, compared to the consensus estimate of $49.37 million. Tilray had a negative return on equity of 62.82% and a negative net margin of 241.79%. Tilray’s revenue was up 127.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.27) EPS. On average, sell-side analysts anticipate that Tilray Inc will post -0.9 earnings per share for the current year.
TLRY has been the subject of a number of research reports. Stifel Nicolaus upped their target price on shares of Tilray from $5.50 to $6.50 and gave the company a “hold” rating in a report on Tuesday, May 12th. Alliance Global Partners reduced their price objective on Tilray from $15.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Zacks Investment Research raised Tilray from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Tuesday, June 2nd. Seaport Global Securities reissued a “neutral” rating on shares of Tilray in a report on Tuesday, March 3rd. Finally, Northland Securities restated a “hold” rating on shares of Tilray in a research report on Tuesday, May 12th. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $12.63.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
See Also: Net Income
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.